Image Name

Enterprise News

Jiangsu Vcare's Class 1 Innovative Drug VC005 Tablets Receives Clinical Trial Approval

Jiangsu Vcare's Class 1 Innovative Drug VC005 Tablets Receives Clinical Trial Approval

In August 2021, VC005 tablets, an innovative drug developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), received clinical trial approval from the NMPA for the indication of inflammatory bowel disease (IBD), with clinical trials set to begin shortly.

Time：2021-08-16 17:38

Jiangsu Vcare Secures New Round of Financing Totaling CNY 100 Million​

Jiangsu Vcare Secures New Round of Financing Totaling CNY 100 Million​

Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) secures another strategic investment of CNY 100 million. This round was jointly invested by Nanjing NII Group, Renpu Capital, and Nanjing Innovation Capital Group. The funds will primarily be used to advance the clinical research of innovative drug pipeline projects like Vicagrel and VC004, while accelerating strategic layout in the CDMO business sector.

Time：2021-07-29 17:31

Vcare Pharmatech Selected as 2021 Nanjing Nurtured Unicorn Enterprise

Vcare Pharmatech Selected as 2021 Nanjing Nurtured Unicorn Enterprise

On June 23, 2021, the list of Nanjing Unicorn and Gazelle Enterprises was announced. Jiangsu Vcare Pharmatech Technology Co., Ltd.(Vcare Pharmatech) was selected as a 2021 Nanjing Nurtured Unicorn Enterprise.

Time：2021-06-24 17:35

Jiangsu Vcare's Novel Drug Vicagrel Receives FDA Approval for Clinical Trials

Jiangsu Vcare's Novel Drug Vicagrel Receives FDA Approval for Clinical Trials

Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced encouraging news regarding its novel antiplatelet drug Vicagrel: The US FDA has provided feedback on the company's submitted IND application for Vicagrel, permitting the company to initiate clinical trials.

Time：2021-03-22 17:35

Jiangsu Vcare Completes Pre-IND Submission for VC005, a Highly Selective JAK1 Inhibitor New Drug

Jiangsu Vcare Completes Pre-IND Submission for VC005, a Highly Selective JAK1 Inhibitor New Drug

Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) successfully submitted a Pre-IND application to the NMPA for its VC005 tablets. VC005 is a highly selective JAK1 inhibitor independently designed by Jiangsu Vcare. It is intended for the clinical treatment of inflammatory bowel disease (IBD), an intestinal autoimmune disorder.

Time：2021-03-12 17:39

Jiangsu Vcare Closes Hundreds-of-Millions-of-RMB Financing Round

Jiangsu Vcare Closes Hundreds-of-Millions-of-RMB Financing Round

Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) has secured financing worth hundreds of millions of CNY in a round led by SDIC Capital, with participation from Fengling Capital. The funds will accelerate Vcare’s CDMO expansion and Phase III clinical research for its innovative drug Vicagrel.

Time：2021-03-08 18:01

Phase II Clinical Researcher Conference of Vicagrel was Successfully Held in Shenyang

Phase II Clinical Researcher Conference of Vicagrel was Successfully Held in Shenyang

On April 14, 2018, phase II clinical researcher conference of Vicagrel capsule, the 13th five-year national science and technology major project was successfully held in Shenyang. Clinical experts, institutional leaders and data management and statistical experts from 16 hospitals attended the meeting. Shenyang military region general hospital is the responsible hospital, and Yaling Han academician is the project leader.

Time：2018-04-18 18:27

Jiangsu Vcare Organized an Emergency Response Training

Jiangsu Vcare Organized an Emergency Response Training

On September 22, 2017, Vcare invited the teachers of Nanjing Science Education Center to teach company employees some emergency knowledge. There were more than 40 employees participated in the training. The main training contents included prevention for accidents, treatment for emergencies, emergency techniques for CPR on-site and first aid, work fatigue, prevention and improvement of common occupational diseases. Employees learned a lot from the training.

Time：2017-09-26 08:41

< 1...891011 >
Jiangsu Vcare Pharmaceutical Technology Co., Ltd.

Company Address:

No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China

Subsidiary NJVcare Website：

en.njvcare.com

Jiangsu Vcare Pharmaceutical Technology Co., Ltd.

Scan to see

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.

SEO

图片名称

苏公网安备32011202001742号

Powerby：www.300.cn nanjing.300.cn